Company Atlasby KadoaStar on GitHub

Regeneron Pharmaceuticals REGN

Regeneron Pharmaceuticals is the 148th largest S&P 500 company by market cap, worth $82.9 billion. 13 directors have filed with the SEC in the last 12 months (who counts), 2 of them executives. 6 other officers are on file. At 30 Jun 2026, Vanguard was its largest institutional holder, with 10.4% of the company.

CEO
Leonard S. Schleifer
Sector
Health Care
Sub-industry
Biotechnology
Headquarters
Tarrytown, New York
Founded
1988
More
Wikipedia
Market cap
$82.9B
148th largest, 23 Oct 2026 close
Revenue
$14.3B
Fiscal year 2025
Price to sales
5.8
Market cap over revenue
Employees
15,410
10-K, 31 Dec 2025
Market cap per employee
$5.4M
Market cap over employees
Connections
2
S&P 500 companies sharing a director or officer

Largest institutional holders

Each fund group's share of Regeneron Pharmaceuticals. Where a company has several share classes, the share is of its total value.

13F filings for the quarter to 30 Jun 2026

These five hold 32.1% of Regeneron Pharmaceuticals.

Source: SEC Form 13F data sets, SEC XBRL shares outstanding 路 All holders

Board and officers

2 people here also hold roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (13)
Leonard S. SchleiferBd. Co-Chair, President & CEOLast filed 5 Jan 2026Bd. Co-Chair, President & CEO
Bonnie L. BasslerDirectorLast filed 8 Jan 2026Director
Michael S. BrownDirectorLast filed 6 Jan 2026Director
N. Anthony ColesDirectorLast filed 6 Jan 2026Director
Joseph L. GoldsteinDirectorLast filed 6 Jan 2026Director
Kathryn GuariniDirectorDirector
Christine A. PoonDirectorAlso at Prudential FinancialLast filed 6 Jan 2026Director
Arthur F. RyanDirectorDirector
David P. SchenkeinDirectorLast filed 6 Jan 2026Director
George L. SingDirectorLast filed 6 Jan 2026Director
Craig B. ThompsonDirectorAlso at Charles River LaboratoriesLast filed 6 Jan 2026Director
George YancopoulosBd. Co-Chair, President & CSOLast filed 5 Jan 2026Bd. Co-Chair, President & CSO
Huda Y. ZoghbiDirectorDirector
Officers (6)
Christopher R. FenimoreEVP Finance CFOLast filed 20 Aug 2026EVP Finance CFO
Joseph J. LarosaEVP General Counsel and SecretLast filed 21 Aug 2026EVP General Counsel and Secret
Marion McCourtEVP CommercialLast filed 3 Sep 2026EVP Commercial
Andrew J. MurphyEVP ResearchLast filed 11 Dec 2025EVP Research
Jason PitofskySVP ControllerLast filed 11 Feb 2026SVP Controller
Daniel P. Van PlewEVP & General Mgr, IndustrialLast filed 11 Dec 2025EVP & General Mgr, Industrial

Source: SEC insider filings (Forms 3, 4 and 5), Regeneron Pharmaceuticals' Form 4 filings 路 All directors and officers

Companies that share people with Regeneron Pharmaceuticals

Each person's title here, then at the other company.

Source: SEC insider filings 路 See the whole network

Regeneron Pharmaceuticals' market cap since December 2008

Weekly, up to 23 Oct 2026

Show equal percentage changes as equal steps.
201020122014201620182020202220242026$82.9B

Source: Yahoo Finance closing prices, SEC XBRL shares outstanding

Workforce

Headcount at 31 Dec 2025

Employees
15,410
As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries (primarily in the United Kingdom, Japan, and Germany).
Regeneron Pharmaceuticals Form 10-K

Source: Regeneron Pharmaceuticals Form 10-K

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 30 Sep 2025 to 30 Sep 2026

Directors and officers sold $12.9 million of stock in 16 sales and made no open-market purchases in the 12 months to 30 Sep 2026.

DatePersonTitleTypeSharesValue
3 Sep 2026SaleMarion McCourtEVP CommercialEVP CommercialSale1,131$970K
2 Sep 2026SaleMarion McCourtEVP CommercialEVP CommercialSale1,215$1.0M
2 Sep 2026SaleKathryn GuariniDirectorDirectorSale400$340K
10 Aug 2026SaleHuda Y. ZoghbiDirectorDirectorSale800$640K
10 Aug 2026SaleKathryn GuariniDirectorDirectorSale400$320K
2 Jul 2026SaleArthur F. RyanDirectorDirectorSale200$130K
1 May 2026SaleArthur F. RyanDirectorDirectorSale100$71K
1 Apr 2026SaleArthur F. RyanDirectorDirectorSale100$78K
2 Mar 2026SaleArthur F. RyanDirectorDirectorSale100$79K
19 Feb 2026SaleHuda Y. ZoghbiDirectorDirectorSale1,638$1.3M

Showing 10 of 16 trades

Source: SEC insider transactions data sets, Regeneron Pharmaceuticals' Form 4 filings

Trades by members of Congress and officials

Trades members of Congress and senior executive branch officials disclosed, including their families'. Amounts are filed as ranges.

Trades from 20 Oct 2023 to 20 Oct 2026

14 people disclosed 27 purchases and 29 sales of Regeneron Pharmaceuticals stock since October 2023.

DateMember or officialTypeAmount
4 Sep 2026Rohit Khanna (House, D-CA)House, D-CA 路 SoldSale$1,001 to $15,000$1K to $15K
23 Jul 2026Donald J Trump (President)President 路 BoughtPurchase$50,001 to $100,000$50K to $100K
17 Jul 2026Donald J Trump (President)President 路 BoughtPurchase$1,001 to $15,000$1K to $15K
7 Jul 2026Rohit Khanna (House, D-CA)House, D-CA 路 BoughtPurchase$1,001 to $15,000$1K to $15K
16 Jun 2026Donald J Trump (President)President 路 SoldSale$1,001 to $15,000$1K to $15K
12 Jun 2026Donald J Trump (President)President 路 SoldSale$100,001 to $250,000$100K to $250K
15 May 2026Gilbert Cisneros (House, D-CA)House, D-CA 路 SoldSale$1,001 to $15,000$1K to $15K
11 May 2026Donald J Trump (President)President 路 BoughtPurchase$100,001 to $250,000$100K to $250K
27 Apr 2026Donald J Trump (President)President 路 BoughtPurchase$15,001 to $50,000$15K to $50K
15 Apr 2026Donald J Trump (President)President 路 BoughtPurchase$1,001 to $15,000$1K to $15K

Showing 10 of 56 trades

Source: House, Senate and OGE disclosures via the Congress trading monitor

Not on file: no WARN layoff notices under its own name since October 2023.